Rupert Haynes

Corporate Officer/Principal presso RADIUS HEALTH, INC.

Health Technology

Profilo

Rupert Haynes is currently the Head-Global Strategy at Radius Health, Inc. He was previously the Chief Executive Officer at FSD Pharma, Inc. from 2018 to 2019.
Prior to that, he held positions as Director-Global Marketing at GW Pharmaceuticals Ltd.
and Head-Global Commercial Operations at Swedish Orphan Biovitrum AB.

Posizioni attive di Rupert Haynes

Società	Posizione	Inizio
RADIUS HEALTH, INC.	Corporate Officer/Principal	01/02/2021

Tutte le posizioni attive di Rupert Haynes

Precedenti posizioni note di Rupert Haynes

Società	Posizione	Fine
FSD PHARMA INC.	Amministratore Delegato	06/02/2019
GW PHARMACEUTICALS PLC	Vendite & Marketing	-
SWEDISH ORPHAN BIOVITRUM AB	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Rupert Haynes

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Rupert Haynes

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
SWEDISH ORPHAN BIOVITRUM AB	Health Technology
FSD PHARMA INC.	Health Technology

Aziende private	2
GW Pharmaceuticals Ltd. GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology GW Pharmaceuticals Ltd. operates as an intermediate holding company and management company for investments in its subsidiaries. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.	Health Technology
Radius Health, Inc. Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.	Health Technology